We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

176 hedge funds and large institutions have $582M invested in Allogene Therapeutics in 2023 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 49 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 21

27% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 49

5% more funds holding

Funds holding: 168 → 176 (+8)

4.26% more ownership

Funds ownership: 77.31% → 81.57% (+4.3%)

15% less capital invested

Capital invested by funds: $686M → $582M (-$104M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

84% less call options, than puts

Call options by funds: $333K | Put options by funds: $2.13M

Holders
176
Holders Change
+8
Holders Change %
+4.76%
% of All Funds
2.8%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
29
Increased
62
Reduced
49
Closed
21
Calls
$333K
Puts
$2.13M
Net Calls
-$1.8M
Net Calls Change
-$2.02M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$24.4M
2
BBA
Baker Bros. Advisors
New York
+$10.1M
3
JP Morgan Chase
JP Morgan Chase
New York
+$8.04M
4
KCM
Kynam Capital Management
New Jersey
+$7.05M
5
Primecap Management
Primecap Management
California
+$5.29M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$14.6M
2
State Street
State Street
Massachusetts
-$6.13M
3
WP
Woodline Partners
California
-$4.68M
4
HA
HHLR Advisors
Cayman Islands
-$3.92M
5
ECM
ExodusPoint Capital Management
New York
-$3.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$4.85M +$840K +130,996 +15%
Ameriprise
27
Ameriprise
Minnesota
$4M +$1.07M +167,036 +26%
Northern Trust
28
Northern Trust
Illinois
$3.95M -$200K -31,231 -4%
Norges Bank
29
Norges Bank
Norway
$3.8M -$736K -114,827 -13%
Rafferty Asset Management
30
Rafferty Asset Management
New York
$3.34M -$510K -79,471 -11%
ECM
31
ExodusPoint Capital Management
New York
$3.34M -$3.1M -483,422 -42%
Nordea Investment Management
32
Nordea Investment Management
Sweden
$3.25M -$46.1K -7,187 -1%
Charles Schwab
33
Charles Schwab
California
$3.21M +$9.56K +1,490 +0.2%
Cerity Partners
34
Cerity Partners
New York
$2.96M +$69.3K +10,800 +2%
Citigroup
35
Citigroup
New York
$2.74M +$1.35M +210,972 +61%
UBS AM
36
UBS AM
Illinois
$2.63M +$3.42M +533,236 New
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$2.53M -$946K -147,511 -22%
Barclays
38
Barclays
United Kingdom
$2.47M +$498K +77,598 +18%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$2.47M +$2.79M +434,954 +669%
CSS
40
Cubist Systematic Strategies
Connecticut
$2.33M +$1.18M +183,643 +64%
Deutsche Bank
41
Deutsche Bank
Germany
$2.21M +$7.7K +1,200 +0.3%
Marshall Wace
42
Marshall Wace
United Kingdom
$2.15M +$2.79M +435,020 New
Renaissance Technologies
43
Renaissance Technologies
New York
$2.12M -$73.1K -11,400 -3%
CBA
44
Coastal Bridge Advisors
Connecticut
$2.01M – – –
IHAM
45
Integral Health Asset Management
New York
$2M +$2.6M +405,000 New
JFG
46
Jefferies Financial Group
New York
$1.96M +$2.54M +396,162 New
Mirae Asset Global Investments
47
Mirae Asset Global Investments
South Korea
$1.8M +$182K +28,305 +8%
Bank of New York Mellon
48
Bank of New York Mellon
New York
$1.73M +$268K +41,747 +14%
TC
49
TwinBeech Capital
New York
$1.61M -$191K -29,791 -8%
RPAM
50
Rhenman & Partners Asset Management
Sweden
$1.49M -$257K -40,000 -12%
1
2
3 4 5

ALLO Hedge Fund Activity: Q1 2023 in Review

176 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q1 2023, worth a combined $582M — down 15% from $686M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ALLO positions and 21 closed out — a net gain of 8 holders — while 62 added to existing stakes and 49 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $24.4M. The largest seller was Millennium Management, cutting an estimated $14.6M.

  • 176 institutional investors held Allogene Therapeutics (ALLO) as of Q1 2023, up from 168 in Q4 2022.
  • Funds reported $582M of Allogene Therapeutics stock for Q1 2023, down 15% quarter-over-quarter.
  • 29 funds opened new Allogene Therapeutics positions in Q1 2023 and 21 closed out, a net change of +8 holders.
  • The largest Allogene Therapeutics buyer in Q1 2023 was Citadel Advisors, an estimated $24.4M added.
  • The largest Allogene Therapeutics seller in Q1 2023 was Millennium Management, an estimated $14.6M sold.

Based on aggregated 13F filings for Q1 2023.